Fig. 5: FRA1 transcriptionally activates AXL, CDK6, and FSCN1.
From: FRA1 drives melanoma metastasis through an actionable transcriptional network
A IGV genome tracks highlight FRA1 occupancy at the AXL, CDK6, and FSCN1 genomic loci. B Overall survival curves of melanoma patients with or without alteration of AXL, CDK6, or FSCN1 (including mutation, copy number alteration, and mRNA changes) in TCGA-SKCM dataset. C Western blot analysis of AXL, CDK6, and Fascin upon FRA1 overexpression or silencing in melanoma cells. D Western blot analysis of FRA1, AXL, CDK6, Fascin, and MITF in human melanocytes (H1, H2, H3, H4), human melanocytes expressing oncogenic BRAFV600E (H1-B, H3-B), and melanoma cell lines. E Representative image of multiplex IHC showing the expression of FRA1, AXL, CDK6, and Fascin in a melanoma microarray containing primary melanoma and metastatic melanoma. F Bar plot showing frequency of Fascin positive samples in primary skin melanomas and lymph node metastatic melanomas. G Pearson correlation analysis of fluorescent intensity of FRA1 and AXL, CDK6, or Fascin. H, I Scatter plots showing the correlation between FRA1 expression and the mean expression of AXL, CDK6, FSCN1 in 1673 cancer cell lines (H, Data extracted from DepMap) and 1,210 tumor tissues (I, Data extracted from cBioPortal). Expression levels are presented as log2(TPM + 1). J qRT-PCR showing the relative expression of AXL, CDK6, and FSCN1 in 1205Lu cells upon expression of PTEN. Data are presented as mean ± SEM and analyzed with Student’s unpaired t test, * P < 0.05, ** P < 0.01, *** P < 0.001.
